Ulcerative ColitisPhase 4NCT00209287
Study of Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis
A Phase 4 study testing Observe patients with inactive ulcerative colitis in people with Ulcerative Colitis, run by Ferring Pharmaceuticals at 1 site in France.
Trial summary
Male or female, 18 years of age or older. Ulcerative Colitis described according usual criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a dosage of 2 to 3 g/day. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ulcerative Colitis
- What is being tested?
- Observe patients with inactive ulcerative colitis
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 6 participants
- Where
- 1 siteFrance
- Study dates
- Jun 2005to Sep 2007
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female, 18 years of age or older.
- Ulcerative colitis described according to usual criteria, diagnosed for at least 1 year.
- Oral maintenance treatment with 5-ASA only for at least 3 months with a dosage of 2 to 3 g/day.
- Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo Clinic) at inclusion.
- Signed informed consent form.
Who cannot join
- Patients allergic to aspirin or salicylates derivatives
- Patients taking the following treatments during the study will be excluded: corticosteroids (oral or rectal route), use of NSAID or Aspirin, any form of sulfasalazine, mesalazine or 4-ASA.
- Patients with known significant hepatic or known function abnormalities and/or creatine clearance ≤ 80 ml/min.
- Patients with history or physical examination findings indicative of active alcohol or drug abuse.
- Women who are pregnant or nursing.
- Patients with a history of disease, including mental/emotional disorder that would interfere with their participation in the study.
Show all 9Show fewer
- Patients who participated in another clinical study in the last 3 months.
- Patients who are unable to comply with the requirements of the protocol
- Female of childbearing potential without efficacious contraception.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Study of Histological Modifications, of Pro-apoptotic Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis (Clinical and Endoscopic Remission) Taking 5-ASA
Male or female, 18 years of age or older. Ulcerative Colitis described according usual criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a dosage of 2 to 3 g/day. Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo Clinic) at the inclusion. Signed informed consent form.
Read the detailed description
Inclusion Criteria:
- Male or female, 18 years of age or older.
- Ulcerative colitis described according to usual criteria, diagnosed for at least 1 year.
- Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a dosage of 2 to 3 g/day.
- Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo Clinic) at inclusion.
- Signed informed consent form.
Exclusion Criteria:
- Patients allergic to aspirin or salicylates derivatives
- Patients taking the following treatments during the study will be excluded: corticosteroids (oral or rectal route), use of NSAID or Aspirin, any form of sulfasalazine, mesalazine or 4-ASA.
- Patients with known significant hepatic or known function abnormalities and/or creatine clearance ≤ 80 ml/min.
- Patients with history or physical examination findings indicative of active alcohol or drug abuse.
- Women who are pregnant or nursing.
- Patients with a history of disease, including mental/emotional disorder that would interfere with their participation in the study.
- Patients who participated in another clinical study in the last 3 months.
- Patients who are unable to comply with the requirements of the protocol
- Female of childbearing potential without efficacious contraception.
- Conditions
- Ulcerative Colitis
- Being tested
- Observe patients with inactive ulcerative colitis
- Keywords
- Ulcerative Colitis for Maintenance of Remission
- Medical subject headings
- Colitis, Ulcerative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Observe patients with inactive ulcerative colitisBehavioural
Observe patients with inactive ulcerative colitis
What is being measured
The primary outcome is the main question the study is designed to answer.
Change between rectal biopsies performed at D1 and D28 of proliferative index
Measured: Its aim was to study histological modifications after Pentasa was stopped in non-active ulcerative colitis.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2005 (estimated)
- Study startJun 2005
- Primary completionDec 2006
- Study completionSep 2007
Why it stopped: Recruitment problematic
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ulcerative ColitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ferring Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Development Support, Study director, Ferring Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00209287
- Sponsor's protocol ID
- Mesalazine 2004-01
- Status last verified
- Apr 2012
- First submitted
- 13 Sep 2005
- Last updated
- 23 Apr 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Histological Modifications, of Pro-apoptotic Effects and of Modifications in Apoptosis Regulators Observed After Stopping 5-ASA Treatment in Patients With Inactive Ulcerative Colitis (Clinical and Endoscopic Remission) Taking 5-ASA
- ClinicalTrials.gov ID
- NCT00209287
- Acronym / sponsor ID
- Mesalazine 2004-01
- Conditions
- Ulcerative Colitis
- Keywords
- Ulcerative Colitis for Maintenance of Remission
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Recruitment problematic
- Enrolment
- 6 participants (actual)
- Lead sponsor
- Ferring PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- Jun 2005
- Primary completion
- Dec 2006 (actual)
- Study completion
- Sep 2007 (actual)
- First posted
- 21 Sep 2005 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Male or female, 18 years of age or older. Ulcerative Colitis described according usual criteria, diagnosed for at least 1 year. Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a dosage of 2 to 3 g/day. Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo Clinic) at the inclusion. Signed informed consent form.
Detailed description
Inclusion Criteria:
- Male or female, 18 years of age or older.
- Ulcerative colitis described according to usual criteria, diagnosed for at least 1 year.
- Oral maintenance treatment with 5-aminosalicylic acid (5-ASA) only for at least 3 months with a dosage of 2 to 3 g/day.
- Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo Clinic) at inclusion.
- Signed informed consent form.
Exclusion Criteria:
- Patients allergic to aspirin or salicylates derivatives
- Patients taking the following treatments during the study will be excluded: corticosteroids (oral or rectal route), use of NSAID or Aspirin, any form of sulfasalazine, mesalazine or 4-ASA.
- Patients with known significant hepatic or known function abnormalities and/or creatine clearance ≤ 80 ml/min.
- Patients with history or physical examination findings indicative of active alcohol or drug abuse.
- Women who are pregnant or nursing.
- Patients with a history of disease, including mental/emotional disorder that would interfere with their participation in the study.
- Patients who participated in another clinical study in the last 3 months.
- Patients who are unable to comply with the requirements of the protocol
- Female of childbearing potential without efficacious contraception.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (participant)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male or female, 18 years of age or older.
- Ulcerative colitis described according to usual criteria, diagnosed for at least 1 year.
- Oral maintenance treatment with 5-ASA only for at least 3 months with a dosage of 2 to 3 g/day.
- Clinical remission for at least 3 months (Mayo Clinic score) and endoscopic remission (endoscopic score of Mayo Clinic) at inclusion.
- Signed informed consent form.
Key exclusion criteria (9 listed)
- Patients allergic to aspirin or salicylates derivatives
- Patients taking the following treatments during the study will be excluded: corticosteroids (oral or rectal route), use of NSAID or Aspirin, any form of sulfasalazine, mesalazine or 4-ASA.
- Patients with known significant hepatic or known function abnormalities and/or creatine clearance ≤ 80 ml/min.
- Patients with history or physical examination findings indicative of active alcohol or drug abuse.
- Women who are pregnant or nursing.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Observe patients with inactive ulcerative colitisObserve patients with inactive ulcerative colitis | Behavioural | – |
Primary outcome
Change between rectal biopsies performed at D1 and D28 of proliferative index
Time frame: Its aim was to study histological modifications after Pentasa was stopped in non-active ulcerative colitis.
Results and safety
The study was stopped early (reason given: Recruitment problematic). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2012.
Related trials for Ulcerative Colitis
Not yet recruitingPhase 1
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Ulcerative Colitis, Crohn's Disease
RecruitingObservational study
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
Inflammatory Bowel Disease, Crohn's Disease
RecruitingObservational study
Ibd CAncer and seRious Infections in France (I-CARE 2)
IBD, Ulcerative Colitis
RecruitingObservational study
Characterization of Colorectal Dysplasic Lesions and Stratification of Their Evolving Risk in Inflammatory Bowel Disease Patients: a Prospective, Observational and Multicenter Study
Crohn Disease (CD), Colitis Ulcerative
Enrolling by invitationPhase 4
MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease
Inflammatory Bowel Diseases, Crohn Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Development Support study director
Ferring Pharmaceuticals
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Observe patients with inactive ulcerative colitis in people with Ulcerative Colitis, run by Ferring Pharmaceuticals at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 23 Apr 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Recruitment problematic). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change between rectal biopsies performed at D1 and D28 of proliferative index (time frame: Its aim was to study histological modifications after Pentasa was stopped in non-active ulcerative colitis.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2012.